Targeting DNA-PK [0.03%]
DNA-PK靶向疗法
Jan Philipp Novotny,Adrian Mariño-Enríquez,Jonathan A Fletcher
Jan Philipp Novotny
This chapter explores the multifaceted roles of DNA-PK with particular focus on its functions in non-homologous end-joining (NHEJ) DNA repair. DNA-PK is the primary orchestrator of NHEJ but also regulates other biologic processes. The growi...
Jeffrey Patterson-Fortin,Alan D D&#x;Andrea
Jeffrey Patterson-Fortin
Polymerase theta (POLθ) is the critical multi-domain enzyme in microhomology-mediated end-joining DNA double-stranded break repair. POLθ is expressed at low levels in normal tissue but is often overexpressed in cancers, especially in DNA ...
Carolina Salguero,Christian Valladolid,Helen M R Robinson et al.
Carolina Salguero et al.
As a key component of the DNA Damage Response, the Ataxia telangiectasia and Rad3-related (ATR) protein is a promising druggable target that is currently widely evaluated in phase I-II-III clinical trials as monotherapy and in combinations ...
Thomas Helleday
Thomas Helleday
The DNA damage response (DDR) protein MTH1 is sanitising the oxidized dNTP pool and preventing incorporation of oxidative damage into DNA and has an emerging role in mitosis. It is a stress-induced protein and often found to be overexpresse...
Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers [0.03%]
结合使用PARP抑制剂和免疫疗法治疗BRCA相关癌症
Geoffrey I Shapiro,Suzanne M Barry
Geoffrey I Shapiro
Poly (ADP-ribose) polymerase (PARP) inhibitors have significantly improved treatment outcomes of homologous recombination (HR) repair-deficient cancers. While the activity of these agents is largely linked to multiple mechanisms underlying ...
Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer [0.03%]
用于克服卵巢癌药物耐药性的组合型DNA损伤反应抑制剂
Dimitrios Nasioudis,Erin M George,Haineng Xu et al.
Dimitrios Nasioudis et al.
The DNA damage response (DDR) results in activation of a series of key target kinases that respond to different DNA damage insults. DDR inhibitors such as PARP inhibitors lead to the accumulation of DNA damage in tumor cells and ultimately ...
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents [0.03%]
PARP抑制剂与同源重组修复障碍诱导型靶向制剂的合理联合用药策略
Elizabeth K Lee,Joyce F Liu
Elizabeth K Lee
Cancers with wild-type BRCA, homologous recombination proficiency, or de novo or acquired resistance to PARP inhibition represent a growing population of patients who may benefit from combinatorial PARP inhibitor strategies. We review targe...
Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges [0.03%]
聚(腺苷二磷酸核糖)聚合酶(PARP)抑制剂与化疗药物的联合应用：前景和挑战
Kyaw Zin Thein,Rajat Thawani,Shivaani Kummar
Kyaw Zin Thein
Better understanding of molecular drivers and dysregulated pathways has furthered the concept of precision oncology and rational drug development. The role of DNA damage response (DDR) pathways has been extensively studied in carcinogenesis...
Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors [0.03%]
PARP抑制剂治疗胰腺癌患者的管理策略
Talia Golan,Maria Raitses-Gurevich,Tamar Beller et al.
Talia Golan et al.
A subset of patients with pancreatic adenocarcinomas (PDAC) harbor mutations that are exploitable in the context of DNA-damage response and repair (DDR) inhibitory strategies. Between 8-18% of PDACs harbor specific mutations in the DDR path...
Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer [0.03%]
靶向雄激素剥夺治疗后前列腺癌的PARP抑制剂的研究进展
Kent W Mouw,Atish D Choudhury
Kent W Mouw
Prostate cancer is a genetically heterogenous disease and a subset of prostate tumors harbor alterations in DNA damage and repair (DDR) genes. Prostate tumor DDR gene alterations can arise via germline or somatic events and are enriched in ...